Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

por Gelbert, Lawrence M., Cai, Shufen, Lin, Xi, Sanchez-Martinez, Concepcion, del Prado, Miriam, Lallena, Maria Jose, Torres, Raquel, Ajamie, Rose T., Wishart, Graham N., Flack, Robert Steven, Neubauer, Blake Lee, Young, Jamie, Chan, Edward M., Iversen, Philip, Cronier, Damien, Kreklau, Emiko, de Dios, Alfonso
Publicado 2014

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft mo...

por Yan, S. Betty, Peek, Victoria L., Ajamie, Rose, Buchanan, Sean G., Graff, Jeremy R., Heidler, Steven A., Hui, Yu-Hua, Huss, Karen L., Konicek, Bruce W., Manro, Jason R., Shih, Chuan, Stewart, Julie A., Stewart, Trent R., Stout, Stephanie L., Uhlik, Mark T., Um, Suzane L., Wang, Yong, Wu, Wenjuan, Yan, Lei, Yang, Wei J., Zhong, Boyu, Walgren, Richard A.
Publicado 2012